Streetbeat News

Revenues

WKHS

Workhorse Group Inc. (WKHS) has received its first fleet order for the W56 step van from Mission Linen Supply. The order consists of 15 vehicles expected to be delivered in 2024. The W56 is a zero emission delivery work van designed for high reliability and serviceability, with a payload capacity of up to 10,000 pounds and a range of up to 150 miles. Workhorse CEO Rick Dauch highlighted the milestone in commercializing their Class 5/6 vehicle, and Mission Linen Supply praised the van's performance in field tests.

Portfolio Pulse from Benzinga Newsdesk

December 20, 2023 | 1:32 pm

GIS

General Mills' stock (GIS) is trading lower following the release of mixed Q2 financial results and an update to its full-year guidance. The company's performance did not align with market expectations, leading to a negative reaction in its stock price.

Portfolio Pulse from Benzinga Newsdesk

December 20, 2023 | 1:31 pm

SPY

The USA Current Account for Q3 reported a deficit of $200.3 billion, slightly better than the estimated deficit of $197.0 billion and an improvement from the previous quarter's deficit of $216.8 billion.

Portfolio Pulse from Benzinga Newsdesk

December 20, 2023 | 1:31 pm

GM

TM

LG Chem is investing $1.6 billion to build the largest cathode plant in the U.S. in Tennessee, with production starting by 2026. The plant will produce NCMA cathode materials for EV batteries and has agreements to supply General Motors and Toyota. The investment aligns with the shift towards cost-effective Sodium-ion batteries and the competitive EV market's demand for advanced battery materials.

Portfolio Pulse from Benzinga Neuro

December 20, 2023 | 1:27 pm

LIPO

Lipella Pharmaceuticals Inc. (NASDAQ:LIPO) celebrates its first year as a public company with significant progress, including FDA feedback on LP-10 for hemorrhagic cystitis, IND approval for LP-310 for Oral Lichen Planus, and orphan drug designations for LP-10 and LP-310. The company is preparing for Phase-2b and Phase-2a trials for these drug candidates, with LP-10 showing positive results in earlier trials.

Portfolio Pulse from Benzinga Newsdesk

December 20, 2023 | 1:10 pm

RLYB

Rallybio Corporation (NASDAQ:RLYB) announced positive preliminary Phase 1 results for RLYB116, a subcutaneous inhibitor of complement component 5, showing over 93% reduction in free C5, suggesting potential as a treatment for generalized myasthenia gravis and other diseases. The company also reported an extension of its cash runway to Q3 2025, focusing on manufacturing enhancements for RLYB116 and advancing RLYB212 for fetal and neonatal alloimmune thrombocytopenia.

Portfolio Pulse from Benzinga Newsdesk

December 20, 2023 | 1:07 pm

EOLS

Evolus, Inc. (NASDAQ:EOLS) has entered into an exclusive licensing agreement with Symatese to distribute four next-generation dermal fillers in the UK and Europe, with regulatory approvals expected in the second half of 2024 and commercialization in 2025. The agreement expands Evolus' international market and complements the launch of Nuceiva, their flagship neurotoxin. Evolus will issue 610,000 shares to Symatese and make milestone payments upon regulatory approvals. The company expects to be fully funded to profitability by 2025 and will pre-announce Q4 and FY23 results and 2024 revenue guidance in January.

Portfolio Pulse from Benzinga Newsdesk

December 20, 2023 | 1:04 pm

MYGN

Myriad Genetics, Inc. has launched the Myriad Collaborative Research Registry (MCRR), formerly known as the Precise Treatment Registry. The MCRR is a comprehensive pan-cancer registry with data from over one million patients, encompassing germline and tumor testing results from Myriad's cancer products. This registry is one of the largest of its kind and is freely available for research to promote clinical data sharing and advance the field of precision medicine.

Portfolio Pulse from Benzinga Newsdesk

December 20, 2023 | 1:03 pm

HAYW

Hayward Holdings (NYSE:HAYW) has received mixed analyst ratings in the last three months, with 5 analysts offering views ranging from bullish to bearish. The average 12-month price target is $13.7, with a high of $16.00 and a low of $12.00, marking a 6.8% decrease from the previous average. Analysts from Stifel and Keybanc have raised and lowered their ratings and price targets, respectively, while Goldman Sachs' Brian Lee has lowered his price target twice. Hayward Holdings, a manufacturer of swimming pool equipment, reported a revenue decline of -10.18% for the quarter ending September 30, 2023, and has financial metrics below industry averages, including a net margin of 5.35%, ROE of 0.92%, and ROA of 0.41%.

Portfolio Pulse from Benzinga Insights

December 20, 2023 | 1:01 pm

STGW

Stagwell (NASDAQ:STGW) has been evaluated by 8 analysts over the last three months, with 7 bullish and 1 indifferent rating. The average 12-month price target is $7.19, with a high of $8.00 and a low of $6.00, marking a 17.07% decrease in the average target. Analysts from firms including Needham, Goldman Sachs, Benchmark, Morgan Stanley, and Craig-Hallum have adjusted their ratings and price targets. Stagwell's financial performance shows a revenue decline of -6.96%, a net margin of 0.11%, ROE of 0.21%, ROA of 0.02%, and a high debt-to-equity ratio of 5.55.

Portfolio Pulse from Benzinga Insights

December 20, 2023 | 1:00 pm